Lai-Yuan Liu, MD
Geriatric Medicine · Miami, FLNPI 1346375540
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 89 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Organogenesis Inc. at 30.5% of the total. Reporting peaked in 2019 at $474 and has fallen 63.1% since, to $175 in 2025.
Across 89 payments — averaging $22.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organogenesis Inc.$606
- Lilly USA, LLC$495
- AstraZeneca$403
- Sunovion Pharmaceuticals Inc.$134
- Zyla Life Sciences, Inc.$83
- Pfizer$47
- plus $220 from 12 others
What the payments were for
- Food & beverage$1,988100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organogenesis Inc. | 17 | $606 |
| Lilly USA, LLC | 27 | $495 |
| AstraZeneca | 20 | $403 |
| Sunovion Pharmaceuticals Inc. | 6 | $134 |
| Zyla Life Sciences, Inc. | 4 | $83 |
| Pfizer | 3 | $47 |
| Amgen | 1 | $22 |
| KCI USA, Inc. | 1 | $21 |
| Abbott | 1 | $20 |
| GSK | 1 | $20 |
| Phadia US Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $19 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Smith+Nephew | 1 | $18 |
| Novartis | 1 | $17 |
| Bioventus LLC | 1 | $15 |
| Novo Nordisk | 1 | $12 |
How this compares
$1,988 in reported general payments places this provider in the 80th percentile of 305 geriatric medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 243 | $233,253 |
| JardianceEmpagliflozin | 130 | $201,450 |
| MounjaroTirzepatide | 62 | $66,022 |
| EliquisApixaban | 56 | $63,356 |
| FarxigaDapagliflozin Propanediol | 18 | $29,188 |
| LinzessLinaclotide | 33 | $28,981 |
| JanuviaSitagliptin Phosphate | 23 | $20,247 |
| TrulicityDulaglutide | 12 | $19,783 |
| Humalog Kwikpen U-200Insulin Lispro | 11 | $16,975 |
| RestasisCyclosporine | 17 | $10,715 |
| SymbicortBudesonide/Formoterol Fumarate | 44 | $10,454 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $9,390 |
| Diclofenac Sodium | 140 | $9,049 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $7,331 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $6,751 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $12 | $235,206254 claims |
| Lilly USA, LLCMounjaro, Trulicity | $495 | $85,80574 claims |
| PfizerEliquis | $47 | $63,35656 claims |
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere | $403 | $46,97373 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $20 | $16,14123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 305 geriatric medicine providers in Florida.
Other geriatric medicine in Miami
- Stuti DangMiami$17K
- Rafael BarrialMiami$2K
- Malcolm FraserBrooksville$359K
- Andrew ScanameoTallahassee$172K
- Naushira PandyaDavie$145K
- Rosemary LairdViera$64K
- Jonathan AppelbaumMonticello$59K
- John PotomskiMelbourne$31K
- Valeria Baldivieso HurtadoWinter Park$28K
- Kae FerberNaples$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.